title: Long-term treatment with golimumab for severe uveitis.
abstract: OBJECTIVE
  To evaluate the long-term efficacy of golimumab in patients with severe recalcitrant uveitis who had inadequate response to previous biologics.
  
  
  METHODS
  Retrospective study (13 patients with JIA, 4 with HLA-B27-associated uveitis). Indication for treatment was active uveitis despite biologics. Golimumab dosing was 50 mg monthly/subcutaneously.
  
  
  METHODS
  uveitis activity, visual acuity improvement, reduction of systemic therapy (corticosteroids/immunosuppressants), adverse events.
  
  
  RESULTS
  Of 17 patients (34 affected eyes), response to golimumab was seen in 14 patients; at last visit uveitis was inactive in 12 patients. Three patients were nonresponders. Mean follow-up time on golimumab was 21.9 months. Visual acuity remained stable in 26 eyes, improved in 7, and worsened in 1. Mean systemic prednisolone dose before and after golimumab was 12.5-3.5 mg/day. One patient developed pulmonary infection.
  
  
  CONCLUSIONS
  Golimumab may be a promising new therapeutic option for severe uveitis patients who have not responded to other biologics.
authors.affiliation: Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele , Milan , Italy and.
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Miserocchi
authors.forename: Giulio
authors.initials: G
authors.lastname: Modorati
authors.forename: Irene
authors.initials: I
authors.lastname: Pontikaki
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Meroni
authors.forename: Valeria
authors.initials: V
authors.lastname: Gerloni
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D001171:Arthritis, Juvenile / Q000150:complications / Q000276:immunology; D001327:Autoimmune Diseases; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D015796:HLA-B27 Antigen / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014605:Uveitis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D015796:HLA-B27 Antigen; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab